title: Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know.
abstract: Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-effects, at best. The present review describes the current status of pharmacogenomics studies regarding germline DNA variants that may alter response and tolerability to chemotherapeutic agents used to treat lung cancer, including perspective studies.
authors.affiliation: Department of Medical and Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy dantonio.chiara@gmail.com.
authors.forename: Chiara
authors.initials: C
authors.lastname: D'Antonio
authors.affiliation: Department of Medical and Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Milano
authors.affiliation: Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
authors.forename: Riccardo
authors.initials: R
authors.lastname: Righini
authors.affiliation: Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
authors.forename: Concetta Elisa
authors.initials: CE
authors.lastname: Onesti
authors.affiliation: Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
authors.forename: Maria
authors.initials: M
authors.lastname: Bassanelli
authors.affiliation: Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
authors.forename: Rosa
authors.initials: R
authors.lastname: Falcone
authors.affiliation: Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
authors.forename: Ida
authors.initials: I
authors.lastname: Paris
authors.affiliation: Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Lauro
authors.affiliation: Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Marchetti
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001693:Biological Transport, Active / Q000187:drug effects / Q000235:genetics; D018736:DNA Adducts; D004260:DNA Repair; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004720:Endonucleases / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics / Q000378:metabolism; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D000076105:X-ray Repair Cross Complementing Protein 1
chemical_list: D000970:Antineoplastic Agents; D018736:DNA Adducts; D004268:DNA-Binding Proteins; D000076105:X-ray Repair Cross Complementing Protein 1; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D004720:Endonucleases
keywords: Pharmacogenomic; cisplatin; gemcitabine; lung cancer chemotherapy; pemetrexed; polymorphism patents; taxanes; vinorelbine